You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 109 No. 5, May 1962 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Correction
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Cyanocobalamin Therapy Effect in Folic Acid Deficiency

RALPH ZALUSKY, M.D.; VICTOR HERBERT, M.D.; WILLIAM B. CASTLE, M.D.

Arch Intern Med. 1962;109(5):545-554.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Introduction

It is currently well established that supraphysiologic doses of folic acid may reverse the hematologic abnormality in patients who are deficient in vitamin B12.1-4 On the other hand, the effect of large doses of cyanocobalamin in folic acid-deficient patients has not been clearly determined. Although responses to cyanocobalamin therapy have occasionally been observed in megaloblastic anemia associated with infancy,5A,5B pregnancy6A and the puerperium,6A,6B cirrhosis of the liver,7,8 intestinal malabsorption,9 and the ingestion of anticonvulsant drugs,10 they have often been suboptimal or inadequate, whereas folic acid therapy induces prompt remission. Interpretation of these results have been complicated by a number of factors, including: (1) lack of reliable laboratory measures of deficiency of vitamin B12 and folic acid, (2) difficulty in control of dietary folic acid intake, especially in the light of recent evidence indicating the therapeutic efficacy of 25µg. and 50µg. . . . [Full Text PDF of this Article]


Author Affiliations

BOSTON

Postdoctoral Research Fellow, National Heart Institute, National Institutes of Health (Dr. Zalusky).; From the Thorndike Memorial Laboratory and Second and Fourth (Harvard) Medical Services, Boston City Hospital, and the Department of Medicine, Harvard Medical School.


Footnotes

Submitted for publication June 22, 1961.

This investigation was supported in part by Grant A-795 (C5) from the National Institutes of Health, Bethesda, Md., and in part by grants from the National Vitamin Foundation and from Eli Lilly & Co.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1962 American Medical Association. All Rights Reserved.